AIDS Therapy

DSMB recommends continuation of phase I trial with VRX496 modified T cells

Published in AIDS Weekly, January 19th, 2004

VIRxSYS Corporation announced that a third patient will be treated in its phase I trial with VRX496 modified T cells.

An independent Data Safety Monitoring board (DSMB) has reviewed initial safety data for its first two patients and unanimously recommended that the trial continue without any modifications.

The clinical trial is the first-ever to use a promising new class of genetic vectors - lentiviral vectors - in humans.

Lentiviral vectors have been shown to deliver genetic payloads stably into primary human cells with high efficiency, a necessary prerequisite for effective genetic therapy. The ongoing trial involves the use of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2004-01-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry